Member Info for dan1nat1

“Zero”

Exactly!

What was the value of Fastjets slots...

40m delayed from yesterday just shown up...that must have cleared someone out?

Are you not offering enough ;)

Thanks for your review cwebb ;) got any opinion on FARN or is it just my comments you want to talk about?

Real bid is ticking up 68.05p despite what looks like a number of sells going through.

Hi Mani,

If Yoda results back up the steroid theory and we have potential to open up the other 2/3's of the market, the advantage is most definitely back with us. I expect these results before we need to start thinking about a fund raise.

Also did someone else looking at an ARDS treatment get an investment off one of the big boys last month? If you were not the large pharma that got it wouldn't you want a piece of FARN so you could at least challenge for the business?

Hi Cyno,

I agree there will be another trial, but we don't know it will have to be a full P3, this from the RNS is making me wonder that "Faron intends to file these data with regulatory authorities (EMA/FDA) in Q1 2019 and to seek advice on the future clinical development of Traumakine in the EU and the US for this precision treatment."

Protocol could be potentially instantly approved based on the approval of INTEREST?

The line on the interview goes a little funny around 3 mins, he is talking about the next trial does he say it would only need to be a small trial?

Same interview he talks about getting it to market for this group 1/3 of patients, then going forward figure out how to make it work for everyone.

Cyno neither you or I can say a full phase 3 trial is or isn't required to get this to market for the targeted 1/3 of patients, and you certainly cannot say it would be 2 years away.

"Now apparently patients must have a specific polymorphism for Traumakine to be effective."

Not true! This latest update is in addition to the on going Yoda trial, it could still be the case that steroids stopped Traumakine working as it should in the patients without the polymorp.

Did you listen to yesterdays interview? https://www.proactiveinvestors.co.uk/LON:FARN/Faron-Pharmaceuticals-Ltd/rns/LSE20181205070002_13891610 4mins in "partner discussions look promising"

I'm surprised they have not thrown there hat in yet, thought they might have tried to steal an early lead on anyone else bidding.

Partners (more than one?) have already been spoken to, so a deal if there is one could happen sooner than you may think.

“Faron Pharmaceuticals Oy (DI) (FARN), which tanked in October after it said its treatment for acute respiratory distress syndrome wasn’t as effective as hoped, is fighting back, up 22.2%, or 14p, to 77p as it said the treatment worked well for patients with a certain genetic mutation.”

Probably before after today’s news...

You are correct, I had not listened to the interview when I posted earlier.

https://www.proactiveinvestors.co.uk/companies/stocktube/11455/faron-pharma-confident-traumakine-could-be-very-effective-for-ards-subgroup-11455.html

This is regarding today's RNS!

Today's announcement could be big enough that we don't need any further partners and can get this to market with a placing next year, we already know everything was put in place for a fast track to manufacturing and market...imagine the value it that!

"Faron intends to file these data with regulatory authorities (EMA/FDA) in Q1 2019 and to seek advice on the future clinical development of Traumakine in the EU and the US for this precision treatment."

We don't yet know a retrial is required for the targeted treatment, the retrial mentioned in the interview was in relation to the use of steroids. They probably want a larger trial with only those patients that have the mutation but maybe not? I expect that is what they want advise on from the regulatory authorities.

Totally agree, I always find the accounting side of business attracts those that prefer numbers to people and it often comes across when you speak to them ;)

"Substantial announcement" was also mentioned...